Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 March 2004, Vol. 103, No. 6, pp. 1976-1977.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weinberg, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Weinberg, K.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow


InsideBlood

Can increased cytokine receptor signaling cause leukemia?

Models of leukemic transformation have focused on binary phenomena: either loss of function of tumor suppressors or gain of function via high-level, dysregulated expression of a dominant transforming oncogene or an abnormal oncogenic fusion protein. The AKR/J mouse is a model of susceptibility to T-lymphoid malignancies. AKR mice develop thymic lymphomas spontaneously or rapidly after neonatal challenge with transforming murine retroviruses, such as the T-lymphomagenic strain SL3-3.1 The mechanisms of increased susceptibility to transformation of AKR lymphohematopoietic progenitors are unknown.

On page 1985 of the present issue of Blood, Laouar and colleagues describe differences in expression of a cytokine receptor, the interleukin 7 receptor (IL-7R), between thymocytes from AKR mice and other strains not prone to lymphoma. The IL-7R is composed of the IL-7R{alpha} and common gamma chain ({gamma}c) subunits. Signal transduction through the IL-7R, like other {gamma}c-containing receptors (IL-2R, IL-4R, IL-9R, IL-15R, IL-21R), involves activation of the Janus kinase–signal transducer and activator of transcription (Jak-STAT) and other signaling pathways. Engagement of the IL-7R with IL-7 produced by thymic epithelial cells is critical for multiple processes in thymocyte development, including induction of both proliferation and survival signals, and differentiation events such as V(D)J recombination of the T-cell receptor genes.

Laouar et al demonstrated that AKR thymocytes express IL-7R{alpha} mRNA and surface protein at significantly higher levels than do other strains of mice. The overexpression of IL-7R{alpha} was specific, as expression of {gamma}c was unaltered. Overexpression of IL-7R{alpha} altered the proportions of immature thymocytes and led to increased survival of AKR thymocytes in vitro. Importantly, bone marrow chimeras containing lymphohematopoietic progenitors from both AKR and non-susceptible strains selectively produced thymocytes derived from the AKR population, while maintaining fixed proportions of non-lymphoid cells. Thus, the AKR-derived thymocytes have a selective advantage in vivo and in vitro over normal cells.


With some caveats, Laouar et al's data strongly suggest that high-level IL-7R expression is a causal event in leukemogenesis. An autocrine or paracrine signaling loop is unlikely since thymocytes do not themselves produce IL-7. A signaling mutation of the IL-7R{alpha} that also affects expression was not formally excluded. The high-level expression of IL-7R{alpha} could be an epiphenomenon downstream of an event that leads to increased expression of other survival signals, as well as IL-7R{alpha}.

Type I cytokine receptors like IL-7R are not thought to be oncogenic, because they lack intrinsic receptor tyrosine kinase activity and need ligand engagement for signal transduction. However, graded differences in signal intensity may be oncogenic. For example, the increased risk of leukemia observed in granulocyte colony-stimulating factor (G-CSF)–treated patients with severe congenital neutropenias may be related to the effects of coding sequence mutations of the G-CSF receptor, leading to enhanced susceptibility to the growth-promoting effects of high-dose G-CSF.2 Recently, T-cell leukemias were described in 2 patients who received gene therapy for {gamma}c-deficient severe combined immune deficiency (X-SCID).3 The X-SCID gene therapy patients were successfully reconstituted with CD34+ hematopoietic progenitors transduced with a constitutively expressed wild-type {gamma}c cDNA under the control of a murine leukemia virus promoter. Elegant analyses of the leukemia cells demonstrated that proviral insertion had occurred near the LMO-2 proto-oncogene locus. What remains unexplained is why leukemia has been observed only in an X-SCID gene therapy trial, and not in other diseases treated with similar vectors carrying different transgenes. Is it possible that high-level expression of {gamma}c, which by itself is not thought to be a transforming gene, led to increased growth factor stimulation via IL-7R or another receptor, thereby promoting the outgrowth of cells containing these insertions?

The relevance of the results of Laouar et al to human leukemogenesis is unknown. The authors' observations indicate that naturally occurring quantitative differences in signal transduction can promote abnormal cell growth and survival. Analyses of single nucleotide polymorphism (SNP) and associated quantitative trait loci (QTL) for human leukemia susceptibility may uncover quantitative differences in gene expression of the sort described by Laouar et al. It will be fascinating to see whether variations in the genome that promote intensity of cytokine receptor signaling, as suggested in the inbred AKR mouse strain, will be associated with increased susceptibility to cancers in humans.

--- Kenneth Weinberg
Childrens Hospital Los Angeles

References

  1. Hays EF, Bristol GC, McDougal S, Klotz J, Kronenberg M. Development of lymphoma in the thymus of AKR mice treated with the lymphomagenic virus SL3-3. Cancer Res. 1989;49: 4225-4230.[Abstract/Free Full Text]

  2. Narparstek E. Granulocyte colony stimulating factor, congenital neutropenia, and acute leukemia. N Engl J Med. 1995;333: 516-518.[Free Full Text]

  3. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302: 415-419.[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Overexpression of IL-7R{alpha} provides a competitive advantage during early T-cell development
Yasmina Laouar, I. Nicholas Crispe, and Richard A. Flavell
Blood 2004 103: 1985-1994. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weinberg, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Weinberg, K.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020